AUG 20·SEC EDGARLow
HERSHBERG ROBERT sold $748K of ADPT
HERSHBERG ROBERT sold 30,664 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $24.40 ($24.39–$24.41, $0.75M total) across 2 trades on 2026-08-18.
StockNASDAQ · US · USDHealthcare · Diagnostics & Research
$ADPT
Adaptive Biotechnologies Corp
Price · $ADPTvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $ADPT in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $18.9M 11 txs
ROBINS CHAD M4× · $14.9M
10b5-1 share of filings18%
Top stories · $ADPTMore →
AUG 20·investing.com
Wednesday’s insider activity: Major buys and sells disclosed
On Wednesday, notable insider trading activity occurred in U.S. stocks. Zentalis Pharmaceuticals (ZLAB) saw a major purchase by Walters Group, while Bakkt (BKKT), Universal Safety Products (UNSP), Advanced Flower Capital (AFCG), and Brilliant Earth (BID) also had significant insider buys. Astera Labs (ALAB), Adaptive Biotechnologies (ADPT), and PACS Group (PACS) reported insider sales, some mandatory for tax purposes. InvestingPro analysis suggests some stocks are undervalued or overvalued.
AUG 20·SEC EDGAR
ROBINS CHAD M sold $14.9M of ADPT
ROBINS CHAD M (CEO and Chairman) sold 600,000 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $24.80 ($24.48–$25.57, $14.88M total) across 4 trades over 2026-08-17 to 2026-08-18.
ADPT sentiment & insider activity
Recent ADPT coverage spans insider activity, financial news and earnings.
In the last 30 days, ADPT insiders filed 11 SEC Form 4 transactions — no purchases and 11 sales ($18.9M). The most active reporter was ROBINS CHAD M, CEO and Chairman, with 4 filings. 18% of those filings were made under pre-arranged Rule 10b5-1 plans.
What's driving ADPT
Significant insider sell by a director may signal concerns about near-term valuation.
Large insider sell may weigh on ADPT.
Large insider sell may pressure the stock short-term.
Insider sale by a director may signal reduced confidence, potentially pressuring the stock short-term.
Guidance raise plus balance-sheet actions (convertible issuance, OrbiMed repayment) and a planned MRD/Immune Medicine separation are likely to re-rate near-term growth and financing risk.
alphai scores every news story that mentions ADPT with an AI model for sentiment and relevance, and aggregates insider trades from Adaptive Biotechnologies Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $ADPT
Score
HERSHBERG ROBERT sold $748K of ADPT
HERSHBERG ROBERT sold 30,664 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $24.40 ($24.39–$24.41, $0.75M total) across 2 trades on 2026-08-18.
1 min readWednesday’s insider activity: Major buys and sells disclosed
On Wednesday, notable insider trading activity occurred in U.S. stocks. Zentalis Pharmaceuticals (ZLAB) saw a major purchase by Walters Group, while Bakkt (BKKT), Universal Safety Products (UNSP), Advanced Flower Capital (AFCG), and Brilliant Earth (BID) also had significant insider buys. Astera Labs (ALAB), Adaptive Biotechnologies (ADPT), and PACS Group (PACS) reported insider sales, some mandatory for tax purposes. InvestingPro analysis suggests some stocks are undervalued or overvalued.
3 min readROBINS CHAD M sold $14.9M of ADPT
ROBINS CHAD M (CEO and Chairman) sold 600,000 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $24.80 ($24.48–$25.57, $14.88M total) across 4 trades over 2026-08-17 to 2026-08-18.
1 min readNEUPERT PETER M sold $3.1M of ADPT
NEUPERT PETER M sold 124,690 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $25.15 ($25.10–$25.23, $3.14M total) across 3 trades on 2026-08-17.
1 min readAdaptive Biotechnologies Corp (ADPT): Results of Operations and Financial Condition
Adaptive Biotechnologies Corp (ADPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results SEATTLE, Jul. 29, 2026 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the gene
6 min readROBINS HARLAN S sold $10.8M of ADPT
ROBINS HARLAN S (Chief Scientific Officer) sold 492,400 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $21.89 ($21.72–$22.12, $10.78M total) across 2 trades on 2026-07-21 under a Rule 10b5-1 trading plan.
2 min readTop Specialty Labs and Diagnostics Stocks, According to BTIG By Investing.com
Investing.com reports BTIG analyst Mark Massaro previewed seven specialty labs and diagnostics stocks as valuations rise. BTIG rates Guardant Health (GH) Buy, $190 target; Natera (NTRA) Buy, $290; BillionToOne (BLLN) Buy, $142; GeneDx (WGS) Buy, $90; Adaptive Biotechnologies (ADPT) Buy, $24; Tempus AI (TEM) Buy, $80; Caris (CAI) Buy, $32, with Q2 expectations and volume or catalyst updates.
5 min readLO FRANCIS sold $2.4M of ADPT
LO FRANCIS (Chief People Officer) sold 105,762 shares of Adaptive Biotechnologies Corp (ADPT) at $22.59 ($2.39M total) on 2026-07-15 under a Rule 10b5-1 trading plan.
1 min readAdaptogenics Health Corp.: Adaptogenics Health Corp. Announces Effective Date of Share Consolidation
Adaptogenics Health Corp. (CSE: ADPT) said the CSE approved a 1-for-4 share consolidation. It will take effect at the open of trading on July 15, 2026. Shares outstanding will fall from 16,397,701 to about 4,099,425, with fractional shares rounded or cancelled. Options and warrants terms will be adjusted.
1 min readAn Adaptive Biotechnologies Insider Sold $8.5 Million in Stock After an 85% Run
Adaptive Biotechnologies said an insider sale by Robins, brother of CEO Chad Robins, involved selling over 386,000 shares for about $8.5M under a March plan, while he still holds about $21.6M. The company reported Q1 revenue up 35% to $70.9M, volume up 41%, net loss narrowing to $20M, and raised full-year MRD guidance to $260M-$270M.
5 min read